Selection and establishment of gefitinib-resistant PC9 cell line and its gene expression profile

Tumor

Volumn 28, Issue 7, 2008, Pages 552-557

  Su, Bo ^a   Su, Chun Xia ^a   Zhang, Hai Ping ^a   Deng, Qin Fang ^a   Zhao, Yin Min ^a   Zhou, Cai Cun ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Cells, cultured; Drug resistance, neoplasm; Gefitinib; Gene expression; Lung neoplasms

Indexed keywords

BETA1 INTEGRIN; COLLAGEN TYPE 4; FIBRONECTIN; GEFITINIB; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE; SOMATOMEDIN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL CYCLE; CELL MUTANT; CELL STRAIN PC 9; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FATTY ACID METABOLISM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; OXIDATIVE PHOSPHORYLATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

EID: 77953430647     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2008.07.003     Document Type: Article

References (5)

1. PARK K, GOTO K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small cell lung cancer [J]. Curr Med Res Opin, 2006,22(3):561-573.
2. PAO W, MILLER V A, POLITI K A, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J]. PLoS Med, 2005,2(3):e73.
3. INUKAI M, TOYOOKA S, ITO S. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer[J]. Cancer Res,2006,166(16):7854-7858.
4. JAIN A, TINDELL C A, LAUX I, et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance[J]. Proc Natl Acad Sci U S A, 2005, 102(33):1858-1863.
5. KWAK E L, SORDELLA R, BELL D W,et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J]. Proc Natl Acad Sci U S A, 2005, 102 (21):7665-7670.